PPT Slide
Remarkably, no YMDD or other mutations occurred with therapy at either dose of adefovir (10 mg or 30 mg, daily) during the 48-week course, either in HBeAg-positive patients or in HBeAg-negative patients, nor was there evidence of virologic resistance.
An increasing duration of adefovir therapy was associated with increasing efficacy in terms of the absence of detectable HBV DNA, highlighting the applicability of adefovir for long-term treatment of chronic HBV infection.
Mailliard & Gollan, N. Engl. J. Med. 348, 848-850 (2003)
“Suppressing Hepatitis B without Resistance – So Far, So Good”